


Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 *Title:*

2 **Isolation and identification of a novel peptide from zein with antioxidant and antihypertensive**
3 **activity**

4 *Authors:*

5 **Yanwei Wang, Haixia Chen*, Xiuming Wang, Shuqin Li, Zhouqin Chen, Jingya Wang, Wei**
6 **Liu**

7 *Institutional affiliation:*

8 **Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of**
9 **Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, P. R. China**

10 *Correspondence author:*

11 **Haixia Chen**

12 *Mailing address:* **Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency,**
13 **School of Pharmaceutical Science and Technology, Tianjin**
14 **University, Tianjin, 300072, P. R. China**

15 *Telephone:* **86-22-27401483**

16 *Fax:* **86-22-27892025**

17 *E-mail address:* **chenhx@tju.edu.cn**

18

19

20

21

22

23

24

25

26

27

28

29

30 **Highlights**

- 31 ● A novel corn peptide was obtained by immobilized enzymes hydrolyzation method.
- 32 ● The corn peptide was prepared by bioassay-guided isolation procedures.
- 33 ● The corn peptide showed stability against thermal treatment and simulation digestion.
- 34 ● The corn peptide showed high antioxidant activity *in vitro* and antihypertensive effects in SHR.

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 **Abstract**

60 The aim of this study is to isolate and identify a novel corn peptide (CPs) from zein with antioxidant
61 and antihypertensive activity based on bioactive-guided isolation procedures. Zein was hydrolyzed
62 by double enzymes immobilized with calcium alginate-chitosan beads and then fractionated and
63 purified. The antioxidant and antihypertensive activities of the CPs fractions were screened by the
64 *in vitro* and *in vivo* assays. The *in vivo* animal studies using spontaneously hypertensive rats (SHRs)
65 confirmed the antihypertensive effects of the CPs peptide, and its angiotensin I-converting enzyme
66 (ACE) inhibitory activity was retained after thermal treatment and simulated gastrointestinal
67 digestion. The primary structure of CPs-2-1 was identified by RP-HPLC-MS/MS and the amino
68 acid sequence was determined as M-I/L-P-P with the molecular weight of 452.3 Da. CPs-2-1
69 showed effective antioxidant and ACE inhibitory activities (IC_{50} values of 220 $\mu\text{g}/\text{mL}$ and
70 70.32 $\mu\text{g}/\text{mL}$, respectively) and it might be a potent candidate for antioxidant functional food or
71 pharmaceuticals for hypertension.

72 **Keywords:** *Corn peptides, identification, antioxidant activity, antihypertension activity, stability*

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 Introduction

89 Bioactive peptides are considered specific protein fragments that are inactive within the sequence
90 of the parent protein. After they are released by enzymatic hydrolysis, they may exert various
91 physiological functions.¹ Biologically active peptides can be released after gastrointestinal digestion,
92 food processing and microbial proteolysis of various animals and plant proteins. It is proved that
93 the bioactivity of peptides were usually affected by the structure and amino acid sequences. The
94 peptides may play various roles, such as antioxidative, antithrombotic, opiate-like, mineral binding,
95 immunomodulatory, antimicrobial, hypocholesterolemic and antihypertensive activities.¹ Peptide
96 therapies can range from anticancer and antimicrobial applications to the treatment of the symptoms
97 of Alzheimer's disease.²

98 Bioactive peptides are the main products of hydrolysis of diverse food proteins. They exert
99 various biological roles based on the structural properties and the amino acid composition and
100 sequences, among of which the antioxidant activity and antihypertensive activity of peptides have
101 more information available. There were some reviews on these two functions of peptides in recent
102 years. High blood pressure was considered as a significant health problem worldwide and important
103 advances had been achieved in the identification of dietary compounds that might contribute to
104 cardiovascular health. Among these compounds, peptides with antihypertensive properties received
105 special attention.³ Plenty of studies had proved reverse relationship between antioxidant intake and
106 diseases. Natural antioxidant peptides had drawn the attention of researchers due to their strong
107 activity and no side effects compared to synthetic antioxidants. Antioxidant activity of bioactive
108 peptides could be attributed to their radical scavenging, inhibition of lipid peroxidation and metal
109 ion chelation properties of peptides.¹ So, more and more studies are focusing on searching for new
110 dietary peptides with antioxidant and antihypertension activities.

111 Corn gluten meal (CGM), which is a byproduct of the corn wet-milling process, contains about
112 60 -71% (w/w) of protein. The major protein fraction in CGM was zein, which composed
113 approximately 68% of the total protein weight. Zein is a kind of alcohol soluble protein, which
114 results in the limited applications in food industry. Furthermore, zein is short of lysine and
115 tryptophan so it is poor in nutritional quality.⁴ However, the zein hydrolysates, corn peptides (CPs)
116 were reported to have many activities such as the inhibition of angiotensin I-converting enzyme

117 (ACE), the alleviation of fatigue, resistance to lipid peroxidation and the facilitation of alcohol
118 metabolism.⁵ In recent years, zein had been used to prepare corn peptides (CPs) by the enzymatic
119 hydrolysis or microbial fermentation methods.⁴ Some studies had been performed for the prepared
120 hydrolysates from CGM protein on its physiological functional properties. CPs was not only taken
121 up easily by the human body where it could perform special physiological functions, it also had high
122 water-solubility and high utilization. ⁴ The preparation methods, physicochemical properties,
123 antioxidant activity, amino acid composition and fractionation by ultrafiltration of antioxidant
124 hydrolysates from corn protein had been studied. In the report of Kim et al, hydrolysis of corn gluten
125 by using commercial proteases could improve its water solubility, and the hydralysates showed
126 powerful angiotensin converting enzyme inhibitory (ACEI) activity.⁶ It was reported that the
127 processing functionality and antioxidative activities of CGM hydrolysates could be proved by using
128 a commercial protease Alcalase, Protamex, or fermentation with *Bacillus natto*.⁷⁻⁹ In the study of
129 Zhou et al, corn protein hydrolysates, prepared by three types of microbial proteases, were separated
130 by sequential ultra-filtration into several fractions, and the fraction of 1-3 kDa showed the highest
131 activity in scavenging peroxy radicals. ⁴ Protamex catalyzed corn gluten meal (CGM) hydrolysis
132 peptides (CHP) were prepared and it was found that the antioxidant activities of CHP were highly
133 correlated to small peptide molecules and high content of antioxidative amino acids.¹⁰ Compared
134 with the commonly used commercial protease, enzyme immobilization was a promising method for
135 high enzyme recovery and extended use of enzyme in different solvents at extreme pH values and
136 temperatures as well as at exceptionally high substrate concentrations.¹¹ In our previous study, a
137 novel enzyme immobilization method, double enzymes (alcalase and trypsin) immobilized in a
138 calcium alginate-chitosan carrier (ATCC) had been used to obtain corn hydrolysates from zein in an
139 ethanol solution.¹² The hydrolysates was found to have good antioxidant activities. However, the
140 structure and the antihypertension activities of CPs are still unknown.

141 In recent years, much work have been done to evaluate the *in vitro* activity of food derived
142 peptides on the angiotensin-I-converting enzyme (ACE), which plays an important role in the
143 regulation of blood pressure. The ACE (dipeptidyl carboxpeptidase, EC3.4.15.1) can cause
144 hypertension by destroying the balance of the two systems the Rennin Angiotensin System (RAS)
145 and Kallikrein Kinin System (KKS).¹³⁻¹⁴ Antihypertensive peptides were reported to inhibit ACE

146 activities by combining the active radical of Zn^{2+} in the obligatory bind site of ACE, so they could
147 exert prominent antihypertensive action. The antihypertensive peptides were usually detected on the
148 *in vitro* antihypertensive studies on ACE inhibitory activities. However, the complete
149 correspondence between *in vitro* and *in vivo* effects and the stability on thermal treatment and
150 simulated gastrointestinal environment treatment had not been demonstrated in many of the
151 published studies.

152 The aim of this study was to identify the primary structure of the CPs obtained from zein by our
153 developed enzyme immobilization method. The antioxidant activities, antihypertensive effects in
154 spontaneously hypertensive rats (SHRs) and ACE inhibitory activity of CPs were evaluated, and
155 the stability on the ACE inhibitory activity was also investigated after the thermal treatment and
156 simulated gastrointestinal environment treatment.

157

158 **Materials and methods**

159 **Materials**

160 Zein was obtained from Gaoyou Rixing Medicinal Materials Co (Jiangsu, China). The alcalase (from
161 bacillus subtilis fermentation), trypsin (from pig pancreas), pepsin (from gastric chief cell) were
162 from Tianjin Nuoao Enzyme Preparation Technology Co. (Tianjin, China). The angiotensin I
163 converting enzyme (ACE, from rabbit lung), hippuryl-histidyl-leucine (HHL) were purchased from
164 Sigma Chemical Co. (St. Louis, MO, USA). The ultra-filtration system (Model No. 8050) and
165 cellulose membranes for zein hydrolysates preparation were purchased from Millipore Co.
166 (Billerica, MA). Sephadex G-10 was purchased from GE Healthcare Bio-Sciences Corp (Uppsala,
167 Sweden). All other chemicals and reagents were purchased locally and were analytical grade.
168 Experimental procedures conformed to the China legislation on Protection of Animals Used for
169 Experimental and other Scientific Purposes.

170 **CPs preparation and purification**

171 The hydrolysis and preparation of CPs was carried out according to our previous studies.¹² Briefly,
172 2.5% (m/v) of zein solution (in 85% ethanol) was hydrolyzed by ATCC beads (containing both
173 alcalase and trypsin simultaneously immobilized within calcium alginate-chitosan composite carrier)
174 at the conditions of pH of 8.5 and the substrate and enzyme mass ratio was 1:1, [S/E]. The hydrolysis

175 reaction was performed at 55°C for 120 min and terminated by filtering out the ATCC beads, then
176 the pH was adjusted to 7.0. The ethanol was removed and the zein hydrolysates were obtained. The
177 hydrolysates were collected and sequentially ultra-filtered through a Millipore 8050 ultrafiltration
178 unit using cellulose membranes with 4 kDa and 6 kDa molecular weight (Mw) limits. Three peptide
179 fractions, fraction 1 (F1), composed of hydrolysate peptides with Mw >6 kDa, fraction 2 (F2),
180 composed of hydrolysate peptides with Mw between 4 and 6 kDa and fraction 3 (F3) composed of
181 hydrolysate peptides with Mw < 4 kDa were obtained, each fraction was collected and lyophilized.
182 Based on the antioxidant activity screening studies, the most active fraction was selected for further
183 purification using a Sephadex G-10 chromatography (50 × 3.0 cm, I.D.), eluted with water at a flow
184 rate of 10 mL/h, and elution peaks were monitored at 280 nm. The main fractions were collected by
185 BS-100A automatic fraction collector (Huxi Analysis instrument Co. LTD, China) and named as
186 CPs-1 and CPs-2, respectively. The fraction with the highest ACE inhibitory activity was dissolved
187 in distilled water, and separated by reversed-phase high performance liquid chromatography (RP-
188 HPLC) on a YMC-Pack ODS-A column (C18, 250 mm×10 mm I.D. YMC Co., Ltd. Japan). For RP-
189 HPLC analysis, mobile phases used in the gradient elution consisted of eluent A consisting of 0.1%
190 trifluoroacetic acid (TFA) in distilled water (v/v); and eluent B of 0.1% trifluoroacetic acid (TFA)
191 in acetonitrile. The separation was performed with a linear gradient from 5 to 50% eluent B at a
192 flow rate of 1.0 ml/min in 40 min. The UV absorbance of the eluent was monitored at 280 nm.
193 Finally, the fraction with the antioxidant and ACE inhibitory activity was collected. This was
194 followed by identification of the amino acid sequence of the peptide.

195 **Scavenging activity against DPPH free radicals**

196 The DPPH scavenging activity of CPs was detected in accordance with our previous study.¹² One
197 hundred microliters of CPs fractions was mixed with 2900 µL DPPH solution (120 µM) in ethanol
198 and incubated in the dark at 37°C for 30 min. The absorbance was recorded at 517 nm. The
199 percentage (%) inhibition of CPs on free radical production by DPPH was calculated and ascorbic
200 acid was used as positive control.

201 **ACE inhibitory activity *in vitro***

202 The ACE inhibitory activity of CPs was analyzed by HPLC method according to the assay
203 developed by Wu et al.¹⁵ Briefly, the substrate HHL was dissolved (5 mM) in 0.1 M sodium-borate

204 buffer (pH 8.3) containing 0.3 M NaCl. The assay was performed by mixing 80 μ L of substrate
205 solution with 30 μ L of CPs fractions (or borate buffer for control). After 10 min of incubation at
206 37°C, 10 μ L of ACE solution (0.1 U/mL) were added and the solution was further incubated at 37°C
207 for 30 min with continuous agitation at 450 rpm. The reaction was stopped by addition of 150 μ L
208 of 1 M HCl and the solution was filtered through a 0.45 μ m nylon syringe filter before being
209 analyzed by RP-HPLC.

210 The HPLC analysis was performed on a C18 column (150 \times 3.0 mm I.D.), particle size 5 μ m with
211 a varian chromatographic system and analytes were detected at the wavelength of $\lambda=228$ nm. The
212 column was eluted at a flow rate of 0.4 mL/min with a two solvents system: (A) 0.05% TFA in
213 water and (B) 0.05%TFA in MeOH. The gradient consisted 5-60% B in 10 min, maintained for 2
214 min at 60% B, then returned to 5% B for 1 min. This was followed by isocratic elution for 4 min at
215 5% B. The evaluation of ACE inhibition was based on the comparison between the concentration
216 of CPs in presence or not and the degree of ACE inhibition (%) was calculated.¹⁶ All the experiments
217 were performed in triplicate.

218 **Thermal stability assays of the CPs on ACE inhibitory activity**

219 CPs fractions (1.0 mg/mL) with different Mw distribution (F1, F2, F3, CPs-1, CPs-2) were thermal
220 treated at different temperatures (30, 50, 70, 90, 110 °C) for 6 min. All solutions were cooled to
221 room temperature before the ACE inhibitory activity analysis *in vitro*. The activity of the CPs prior
222 to treatment was considered as 100%. All the experiments were performed in triplicate.

223 **Stabilities against simulated gastrointestinal digestion on ACE inhibitory activity**

224 Stabilities of CPs fractions against gastric proteases *in vitro* were assessed using pepsin and
225 pancreatin according to the reported methods of Elizabeth et al.¹⁷ and Escudero et al.¹⁸with some
226 modifications. Pepsin (0.2 mg) was added to aqueous solutions of CPs (1:100; enzyme to substrate
227 ratio), the mixture was adjusted at pH 2.0 using 1 M HCl and incubated at 37°C. After 120 min, the
228 pH was adjusted to 7.5 by adding 1 M NaHCO₃. Then, pancreatin (0.4 mg) was added at a 1:50
229 enzyme to substrate ratio, and the solution was further incubated at 37 °C for 120 min. The reaction
230 was stopped by heating at 95°C for 10 min in a water bath, followed by cooling at room temperature.
231 After the simulated gastrointestinal digestion, the peptides were freeze-dried and then reconstituted
232 for ACE inhibitory activity determination. Experiments for each sample were done in triplicate. The

233 inhibitory activity of the CPs prior to digestion was considered as 100%.

234 ***In vivo* assay of CPs on antihypertensive activity**

235 Antihypertensive effects of the purified peptides were carried out in male SHR_s (Age 10-15 weeks,
236 Weight 220-260 g, No. 11003800004211, Beijing HFK Bioscience Co., China). All rats were cared
237 and fed in accordance with the standards for laboratory animals established by the People's Republic
238 of China (GB14925-2001) and Animal handling followed the Declaration of Helsinki and the
239 Guiding Principles in the Care and Use of Animals. The rats were allowed to acclimate a week prior
240 to the experiments. Tail systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
241 measured by the noninvasive tail-cuff method¹⁹ with a computer-assisted BP-2010 Series tail
242 measurement equipment (Softron Beijing Biotechnology Co., Ltd.). SHR_s with tail SBP higher than
243 175 mmHg and DBP higher than 120 mmHg were used in this study. The SHR_s were divided into
244 four groups with four rats each and administered the following treatments: (a) Zein hydrolysate
245 before ultrafiltration dissolved in physiological saline at the dose of 50 mg/kg body weight, (b) CPs-
246 2 dissolved in physiological saline at the dose of 10 mg/kg body weight, (c) the positive control
247 captopril dissolved in physiological saline at the dose of 10 mg/kg body weight, and (d)
248 physiological saline only. Each group received a 1 mL dose of each treatment via oral gavage. The
249 SBP and DBP were measured both before administration (zero time) and 2, 4, 6, 8, 12 and 24 h
250 post-administration. Physiological saline alone and captopril served as negative and positive
251 controls, respectively. To measure BP, SHR_s were pre-warmed at 37°C for 10 min in a warming
252 box.

253 **HPLC-MS/MS analysis**

254 Amino acid sequence of the purified peptide from zein hydrolysate was determined by RP-HPLC-
255 MS-MS using Mass Spectrometry (mior OTOF-QII MS, Bruker Dalton Company, USA) with an
256 electro-spray ionization (ESI) source. The elution was performed using a mobile phase consisting
257 of water + 0.1% trifluoroacetic acid (eluent A) and acetonitrile + 0.1% trifluoroacetic acid (eluent
258 B). Gradient elution was carried out according to the following process: 0-40 min, A 95-50%, B 5-
259 50%. Mass spectrometry conditions: ESI⁺ ion source; spray voltage was 4500 V; Set dry heater was
260 180°C; the set nebulizer gas (N₂) was 0.8 Bar; the flow rate of drying gas (N₂) was 60.0 L/min;
261 spectra were recorded over the mass/charge (m/z) range of 50-1500. The peptide sequencing was

262 performed by processing the MS-MS spectra using the mass spectrometry database (Swiss Prot) as
263 well as manual calculation.

264 **Statistical analyses**

265 The values were expressed as the means \pm standard deviation (SD) of three replicates. Statistical
266 analysis of the data was done using the SAS software (SAS Institute Inc., Cary, NC, USA). The
267 differences in mean were calculated using the Duncan's multiple-range tests for means with 95%
268 confidence limit ($P < 0.05$).

269

270 **Results and discussion**

271 **Purification of peptide CPs-2-1**

272 Based on our previous studies, the CPs fraction with $M_w < 4$ kDa, F3, showed the stronger
273 antioxidant activities than the other two fractions F1, > 6 kDa and F2, 4 kDa - 6 kDa.¹² Herein, the
274 most active fraction F3 was selected for the further purification using a Sephadex G-10
275 chromatography in the study, and two fractions CPs-1, CPs-2 (Fig.1A) were collected and
276 lyophilized for the determination of their ACE inhibitory activity. The active fraction CPs-2 was
277 then selected for the further isolation and preparation on RP-HPLC chromatography and the main
278 fraction CPs-2-1 was obtained (Fig. 1B).

279 **ACE inhibitory activity of CPs *in vitro***

280 ACE activity leads to an increase in the blood pressure by producing the vasoconstrictor peptide
281 angiotensin II and by degrading the vasodilator peptide bradykinin. Inhibitors of ACE are thus used
282 as therapeutic agents against hypertension. Many kinds of peptides derived from food proteins are
283 known to exhibit ACE inhibitory activity and are considered to be milder and safer as compared to
284 synthetic drugs.²⁰ Furthermore, these peptides are multifunctional and easily absorbed in the
285 gastrointestinal tract.²¹ The ACE inhibitory activity of different CPs fractions was presented in Fig.2.
286 The results showed that the ACE inhibition capacity was increased with decrease of CPs M_w
287 distribution when all the fractions were detected at the same concentration of 1.0 mg/mL. The
288 highest activity was exhibited by fraction CPs-2 with the ACE inhibitory activity of 79.3%, which
289 had the smallest molecular weight distribution. While the fraction F1, with the highest molecular
290 weight distribution, showed the lowest inhibitory effects (48.6%). The results were in accordance

291 to the report of Huang et al., in which the corn peptide fraction with $M_w < 3$ kDa showed the highest
292 ACE-inhibitory activity.²² In other studies on plant protein and peptides such as grass carp protein
293 and peanut protein hydrolysate, it was also found that ACE inhibition capacity was increased with
294 the increase of hydrolysis and the $M_w < 3$ kDa fraction showed the higher ACE inhibitory activity
295 than the fractions with M_w of 3-10 kDa or above 10 kDa.^{20,23} It could be suggested that the
296 molecular size of the peptide played an important role in its ACE-inhibitory activity and most of
297 them were less than 3 kDa.

298 **Effect of thermal treatment on ACE inhibitory activity of CPs**

299 The generated bioactive peptides can be directly ingested either raw or heat treated, or incorporated
300 into other processed products. In this case, it is necessary to consider the stability of the ACE
301 inhibitory activity among the typical temperature conditions. To investigate the thermal stability of
302 CPs, the peptides fractions were subjected to incubation at temperature 30, 50, 70, 90 and 110 °C
303 for 6 min and the residual activity was measured. The ACE inhibitory activity of the CPs prior to
304 thermal treatment was used as control and considered as 100%. All the assayed CPs fractions
305 remained ACE inhibitory activity after the thermal treatment at different levels (Fig.3A). CPs-2
306 showed the highest relative ACE inhibitory retention rate (RACEI) after 50 °C treatment (179.6%).
307 ACE inhibitory rates of CPs-2 increased than that of the original one when it was thermal treated at
308 30, 50, 70 and 90 °C (138.9%, 179.6%, 142.4%, 152.0%), and 99% relative activity was still
309 remained after the thermal treatment at 110 °C. ACE inhibitory activity of F1 was also increased
310 with the treatment from 50 to 110 °C (131.0%, 114.6%, 104.3%, 113.1%, respectively) except
311 treatment at 30 °C (40.1%). ACE inhibitory activities of F2 were increased after 50 °C (141.3%) and
312 110 °C (122.3%) treatment. The inhibitory rate was increased when F3 was heated at 50 °C to 90 °C
313 (130.3%, 119.1%, 137.8%), and the rate was increased when CPs-1 was treated at these
314 temperatures except for that at 50 °C. For the CPs fractions F1, F2 and F3, thermal treatment at 30
315 °C resulted in the decrease of ACE inhibitory activity with the retention rates of 40.1%, 80.1% and
316 75.6%, respectively. Different fractions showed different activity retention tendency, among which
317 CPs-2 showed the highest stability against thermal treatment. The reason might be due to the
318 different composition and molecular weight distribution.

319

320 **Effect of gastrointestinal digestion *in vitro* on ACE inhibitory activity of CPs**

321 Proteolytic enzymes can generate bioactive peptides during digestion that were inactive within the
322 parent protein.²⁴ ACE inhibitory peptides could exert *in vivo* antihypertensive effect if they reach the
323 blood stream in an active form.²⁵ So, after oral ingestion, peptides need to resist complete hydrolysis
324 by gastrointestinal enzymes and brush border peptidases, and be able to pass through the intestinal
325 wall with preserving their biological activity.¹⁸ To evaluate the stability under digestion by
326 gastrointestinal enzymes, the CPs fractions was incubated with various gastrointestinal proteases
327 including pepsin and pancreatin, and then the ACE inhibitory activity was detected. Compared with
328 the ACE inhibitory activity of the undigested control (considered as 100%), the relative ACE
329 inhibitory retention rates (RACEI) of digested CPs fractions by gastric proteases were 82.8%,
330 126.6%, 76.8%, 63.2% and 72.1% for F1, F2, F3, CPs-1 and CPs-2, respectively. Though there were
331 some decrease on the ACE inhibitory activity of F1, F3, CPs-1 and CPs-2, they were all above 63%.
332 Especially, the activity of fraction F2 was increased to 126.6% after the *in vitro* digestion treatment
333 (Fig.3B), suggesting that the peptides might be resistant to digestion in the gastrointestinal tract or
334 they might be partially degraded into smaller peptides with the antihypertensive biological activity.
335 These results were agreed with the previous studies on other peptides, in which it was showed that
336 small peptides still presented ACE inhibitory activity after digestion.¹⁸ These results indicated that
337 CPs was relatively stable against gastrointestinal proteases of pepsin and pancreatin. The related
338 mechanism will need further study.

339 **Antihypertensive effects of CPs in SHR**

340 The antihypertensive effect of CPs was evaluated by measuring the changes in the SBP and DBP of
341 SHR during a 24 h observation period following a single gastric intubation (Fig.4). In the negative
342 control group (normal saline), no significant changes were found in the SBP and DBP of SHR during
343 the 24 h after administration. After administration of zein hydrolysate, there were decrease on SBP
344 (-24.5 mmHg) and DBP (-19.8 mmHg) at 8 h after administration, while, there was no significant
345 changes were found on SBP during the 24 h after administration (3.8 mmHg). Furthermore,
346 administration of CPs-2 (10 mg/kg) and captopril (10 mg/kg) caused significant decrease of the
347 blood pressure (BP) at 2, 4, 6, 8 and 12 h after administration ($p < 0.05$). CPs-2 administration
348 resulted in the decrease of 42.5 mmHg of SBP change and 17.1 mmHg of DBP change at 8 h and

349 44.6 mmHg of SBP change and 10.2 mmHg of DBP change at 12 h, which was even better than the
350 positive control captopril (SBP with 22.7 mmHg change and DBP with 13.9 mmHg change at 8 h,
351 SBP with 17.7 mmHg change and 7.9 mmHg change of DBP at 12 h). The *in vivo* effects of CPs
352 were in accordance with the results of ACE inhibitory activity of CPs. In the review of Martinez-
353 Maqueda et al., it was stated that the complete correspondence between *in vitro* and *in vivo* effects
354 had not been demonstrated in many of the published studies because of the discrepancy between
355 ACE inhibitory (ACEI) and antihypertensive activity of peptides.³ The reason might be due to their
356 further degradation during gastrointestinal digestion, the impossibility to reach the target organ in
357 the organism in a sufficient amount or because other mechanisms different than ACE inhibition
358 might be involved. In this study, the peptide CPs showed relatively good gastrointestinal digestion
359 stability and so there was correspondence between *in vitro* and *in vivo* effects. Results suggested
360 that the ACE inhibitory peptide obtained through double enzymes immobilized with calcium
361 alginate-chitosan beads could provide an obvious antihypertensive effect in SHR at a dosage of 10
362 mg/kg per rat.

363 **Identification of CPs-2-1 by RP-HPLC-MS/MS.**

364 The fraction CPs-2, with the strongest ACE inhibitory activity was then separated by reversed-phase
365 RP-HPLC, and the main components CPs-2-1 was obtained and subsequently subjected to RP-
366 HPLC-MS/MS for peptide sequence identification. The accurate relative molecular mass of the
367 peptide, deduced from the m/z value of $[M+H]^+$ by subtraction of one mass unit for the attached
368 proton, was 452.3 Da (Fig. 5A). The $[M+H]^+$ ion at m/z 453.3 suggested a tetrapeptide composed
369 of the amino acids Met, Ile/Leu, Pro and Pro. As shown in Fig. 5B, the m/z $453.3-322.3=131.0$,
370 which indicated the first amino acid from the N-terminal was a Met (M) residue and m/z 322.3 was
371 the y_3 ion. Similarly, m/z $322.3 (y_3) - 209.2 (y_2) = 113.1$, thus we could infer that the second amino
372 acid from the N-terminal was a Leu/Ile (L/I) residue, in which L and I were isomers. Next, $y_2 - y_1 =$
373 m/z $209.2 - 114.1 = 95.1$, which suggested that the third amino acid of the N-terminal was Pro (P)
374 residue. Finally, the $y_1 = 114.1$, suggested that the C-terminal was Pro (P) residue. From the manual
375 calculation process above, the amino acid sequence of CPs-2-1 was determined as M-I/L-P-P. The
376 results of peptide CPs-2-1 sequencing were subjected to a manual evaluation as described by Chen
377 et al.²⁶ the mass signal and corresponding fragmentation spectra matched to a single peptide

378 fragment by manual calculation. In this study, the amino acids analysis of the peptide CPs-2-1 was
379 agreed with the study on amino acids composition of zein, in which zein was rich in Leu (20%), Pro
380 (10%) and Ala (10%) and lacked of alkaline and acidic amino acids.²⁷ The molecular weight and
381 the amino acids composition were accord with the reports that the bioactive peptides were in the
382 size of 2-20 amino acids and molecular masses of less than 6000 Da.¹

383

384 **DPPH radical scavenging effects and ACE inhibitory activities of CPs-2-1**

385 The DPPH radical scavenging effects and ACE inhibitory activities of CPs-2-1 were shown in Table
386 1. Peptide CPs-2-1 showed antioxidant and ACE-inhibitory activities in dose dependent manner
387 with the IC₅₀ values of 220 µg/mL and 70.32 µg/mL, respectively. The antioxidant activity of CPs-
388 2-1 was stronger than the previous report of Wang et al., in which corn gluten meal (CGM) was
389 hydrolyzed using two proteases (Alcalase and Protamex) to produce the antioxidant peptide with
390 the EC₅₀ value of 950 µg/mL on scavenging activity against DPPH free radicals.²⁶ In the study of
391 Huang et al.,²² IC₅₀ values of ACE-inhibitory activities of the corn peptides with different molecular
392 weight were 440, 290, 1270 µg /mL for Mw< 1 kDa permeate, Mw< 3 kDa permeate, Mw< 5 kDa
393 permeate, respectively, which were larger than the IC₅₀ value of CPs-2-1, suggesting that CPs-2-1
394 showed more effective ACE-inhibitory activities than the reported one. The difference might be due
395 to the different composition, structure, and hydrophobicity between the CPs-2-1 and the reported
396 peptides. CPs-2-1 was a potent candidate for antioxidant and ACE-inhibitory peptide product. The
397 purified peptide might be used in functional food products as a bioactive component with good
398 antioxidant and ACE-inhibitory activities.

399 It was reported that Tyr, Trp, Met, Lys, Cys, and His were examples of amino acids that could
400 cause antioxidant activity.²⁹ Amino acids with aromatic residues could donate protons to electron
401 deficient radicals. This property could improve the radical-scavenging properties of the amino acid
402 residues.³⁰⁻³¹ In the amino acid composition of CPs-2-1, aromatic amino acids, Phe, was also
403 presented, which had been shown to act positively as direct radical scavengers. The amino acid
404 sequence of CPs-2-1 was agreed with the report that at penultimate C-terminal position, aliphatic
405 (V, I, and A), basic (R) and aromatic (Y and F) residues were frequently found in ACE inhibitory
406 peptides, while aromatic (W, Y, and F), proline (P) and aliphatic (I, A, L and M) residues were

407 preferred at the ultimate C-terminal end of peptides.³² Jun et al. reported that oral administration of
408 Ile-Gln-Pro at a dosage of 10 mg/kg showed significant decreases of SBP and DBP in SHR.³³ The
409 amino acids composition and sequence M-I/L-P-P might play great roles to the antioxidant and
410 antihypertensive activities. This was the first time that the peptide M-I/L-P-P was isolated from food
411 protein with high ACE inhibitory activity.

412

413 **Conclusion**

414 Under the bioassay-guided isolation procedure, M-I/L-P-P, a peptide with effective antioxidant and
415 antihypertensive activity, was identified by RP-HPLC-MS/MS. This peptide was from zein
416 hydrolysate fraction by double enzymes immobilized with calcium alginate-chitosan beads in the
417 ethanol phase with the molecular weight of 452.3 Da. The antihypertensive activities were relatively
418 well retained after thermal treatment and simulated gastrointestinal environment treatment. There
419 were good correspondence for the *in vitro* and *in vivo* studies of CPs on antihypertensive effects.
420 The new peptide might be a potent candidate for functional food or pharmaceuticals for
421 hypertension.

422

423 **Acknowledgements**

424 This work was supported by a grant from National High Technology Research and Development
425 Program ("863"Program) of China (Grant No. SS2013AA100207) and the National Natural Science
426 Foundation of China (NSFC 31371879).

427

428

429

430

431

432

433

434

435

436 **References**

- 437 1 B. H. Sarmadi and A. Ismail, Antioxidative peptides from food proteins: A review, *Peptides*,
438 2010, 31, 1949-1956.
- 439 2 C. Fitzgerald, R.E. Aluko, M. Hossain, D. K. Rai and M. Hayes, Potential of a renin inhibitory
440 peptide from the red seaweed *Palmaria palmata* as a functional food ingredient following
441 confirmation and characterization of a hypotensive effect in spontaneously hypertensive rats,
442 *J. Agric. Food Chem.*, 2014, **62**, 8352-8356.
- 443 3 D. Martinez-Maqueda, B. Miralles, I. Recio and B. Hernandez-Ledesma, Antihypertensive
444 peptides from food proteins: a review, *Food Funct.*, 2012, 3, 350-361.
- 445 4 K. Zhou, S. Sun and C. Canning, Production and functional characterization of antioxidative
446 hydrolysates from corn protein via enzymatic hydrolysis and ultrafiltration, *Food Chem.*, 2012,
447 **135**, 1192-1197.
- 448 5 F. Zhang, J. Zhang and Y. Li, Corn oligopeptides protect against early alcoholic liver injury in
449 rats. *Food Chem. Toxicol.*, 2012, **50**, 2149-2154.
- 450 6 J. Kim, J. Whang, K. Kim, J. Koh and H. Suh. Preparation of corn gluten hydrolysate with
451 angiotensin I converting enzyme inhibitory activity and its solubility and moisture sorption,
452 *Process Biochem.*, 2004, **39**, 989-994.
- 453 7 X.Q. Zheng, J.T. Wang, X.L. Liu, Y. Sun, Y.J. Zheng, X.J. Wang and Y. Liu. Effect of
454 hydrolysis time on the physicochemical and functional properties of corn glutelin by Protamex
455 hydrolysis, *Food Chem.*, 2015, **172**, 407-415.
- 456 8 X.Q. Zheng, X. L. Liu and Z.S. Liu. Production of fermentative hydrolysate with antioxidative
457 activity of extruded corn gluten meal by *Bacillus natto*. *Appl. Mech. Mater.*, 2012, **138**, 1142-
458 1148.
- 459 9 X.Q. Zheng, X.L. Liu, X.J. Wang, J. Lin and D. Li, Production of hydrolysate with
460 antioxidative activity by enzymatic hydrolysis of extruded corn gluten. *Appl. Microbiol.*
461 *Biotech.*, 2006, **73**, 763-770
- 462 10 C.S. Zhou, J.L. Hu, H.L. Ma, A.A. Yagou, X.J. Yu, J. Owusu, H.Y. Ma and X.P. Qin.
463 Antioxidant peptides from corn gluten meal: Orthogonal design evaluation. *Food Chem.*, 2015,
464 **187**, 270-278

- 465 11 F. Chen, F. Zhang and F. Du, A novel and efficient method for the immobilization of
466 thermolysin using sodium chloride salting-in and consecutive microwave irradiation,
467 *Bioresource Technol.*,2012, **115**, 158-163.
- 468 12 Y. Wang, H. Chen, J. Wang and L.S. Xing, Preparation of active corn peptides from zein
469 through double enzymes immobilized with calcium alginate-chitosan beads, *Process Biochem.*,
470 2014, **49**, 1682-1690.
- 471 13 D. Coates, The angiotensin converting enzyme (ACE). *Int J Biochem Cell Biol.* , 2003,**35**,
472 769-773.
- 473 14 W.J. Qu, H.L.Ma., Z.L. Pan, L. Luo, Z.B. Wang, R.H. He. Preparation and antihypertensive
474 activity of peptides from *Porphyra yezoensis*. *Food Chem.*, **2010**, 123, 14-20.
- 475 15 J. Wu, R.E. Aluko and A.D. Muir, Improved method for direct high-performance liquid
476 chromatography assay of angiotensin-converting enzyme-catalyzed reactions. *J. Chromatogr.*
477 *A*, 2002, **950**, 125-130.
- 478 16 V. Lahogue, K. Réhel and L. Taupin, A HPLC-UV method for the determination of
479 angiotensinI-converting enzyme (ACE) inhibitory activity, *Food Chem.*,2010, **118**, 870-875.
- 480 17 E. Escudero, M.A. Sentandreu and F. Toldrá, Characterization of peptides released by *in vitro*
481 digestion of pork meat, *J. Agric. Food Chem.*,2010, **58**, 5160-5165.
- 482 18 E. Escudero,L. Mora and F. Toldrá, Stability of ACE inhibitory ham peptides against heat
483 treatment and *in vitro* digestion, *Food Chem.*,2014,**161**, 305-311.
- 484 19 P. Ruiz-Giménez, A. Ibáñez, J.B. Salom, J.F. Marcos, J.J. López-Díez, S. Vallés, G. Torregrosa,
485 E. Alborch and P. Manzanares. Antihypertensive properties of lactoferricin B-derived peptides,
486 *J. Agric. Food Chem.*2010, **58**, 6721-6727.
- 487 20 R. Hartmann, H. Meisel. Food-derived peptides with biological activity: from research to food
488 applications, *Curr. Opin. Biotech.*, 2007, **18**, 163-169.
- 489 21 S.N. Jamdar, V. Rajalakshmi, M.D. Pednekar. Influence of degree of hydrolysis on functional
490 properties, antioxidant activity and ACE inhibitory activity of peanut protein hydrolysate,
491 *Food Chem.*, 2010, **121**, 178-184.
- 492 22 W.H. Huang, J. Sun, H. He, H.W. Dong and J.T. Li. Antihypertensive effect of corn peptides,
493 produced by a continuous production in enzymatic membrane reactor, in spontaneously

- 494 hypertensive rats. *Food Chem.*, 2011, 128, 968-973
- 495 23 J. Chen, Y. Wang and Q. Zhong, Purification and characterization of a novel angiotensin-I
496 onverting enzyme (ACE) inhibitory peptide derived from enzymatic hydrolysate of grass carp
497 protein, *Peptides*, 2012, **33**, 52-58.
- 498 24 J. Chen, Y. Wang and Q. Zhong, Purification and characterization of a novel angiotensin-I
499 onverting enzyme (ACE) inhibitory peptide derived from enzymatic hydrolysate of grass carp
500 protein, *Peptides*, 2012, **33**, 52-58.
- 501 25 E. Escudero, M.A. Sentandreu and K. Arihara, Angiotensin I-converting enzyme inhibitory
502 peptides generated from in vitro gastrointestinal digestion of pork meat, *J. Agric. Food*
503 *Chem.*, 2010, **58**, 2895-2901.
- 504 26 Y. Chen, S.W. Kwon and S.C. Kim, Integrated approach for manual evaluation of peptides
505 identified by searching protein sequence databases with tandem mass spectra, *J. Proteome*
506 *Res.*, 2005, **4**, 998-1005.
- 507 27 H.Wu and L.L. Li. Preparation of corn peptide in non aqueous media and its antialcoholism
508 activity *in vitro*, *Food and Fermentation Industries (in Chinese)*, 2010, **12**, 14.
- 509 28 X.J. Wang, X.Q. Zheng, N.K. Kopparapu, W.S. Cong, Y.P. Deng, X.J. Sun and X.L. Liu.
510 Purification and evaluation of a novel antioxidant peptide from corn protein hydrolysate .
511 *Process Biochem.*, 2014, 49, 1562-1569
- 512 29 W.Y. Wang and E.G. De Mejia, A new frontier in soy bioactive peptides that may prevent age-
513 related chronic diseases. *Compr. Rev. Food. Sci. Food Saf.*, 2005, 4, 63-78.
- 514 30 N. Rajapakse, E. Mendis, W.K. Jung, J.Y. Je and S.K. Kim, Purification of a radical scavenging
515 peptide from fermented mussel sauce and its antioxidant properties, *Food Res Int* 2005, 38,
516 175-182.
- 517 31 J. Ren, M. Zhao and J. Shi, Purification and identification of antioxidant peptides from grass
518 carp muscle hydrolysates by consecutive chromatography and electrospray ionization-mass
519 spectrometry, *Food Chem.*, 2008, **108**, 727-736.
- 520 32 H. Iroyukifujita, K. Eiichiyokoyama and M. Yoshikawa, Classification and antihypertensive
521 activity of angiotensin I - converting enzyme inhibitory peptides derived from food proteins.
522 *J. Food Sci.*, 2000, **65**, 564-569.

523 33 J. Lu, D.F. Ren and Y.L. Xue, Isolation of an antihypertensive peptide from alcalase digest of
524 *Spirulina platensis*, *J. Agric. Food Chem.*, 2010, **58**, 7166-7171.

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552 **Related table**

553 **Table 1** The IC₅₀ values of CPs-2-1 on DPPH radical scavenging effects and ACE inhibitory
554 activities (µg /mL)

Sample	DPPH radical scavenging activities	ACE inhibitory activities
CPs-2-1	220 ±2.63	70.32 ±0.61

555 Values are presented as means ±SD (n=3).

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573


574

575

576

577

578 Related Figures



579

580

581


582

583

584

585

586



587

588

589

590 **Fig.1.**Purification of peptide CPs-2-1. (A: Sephadex G-10 chromatogram; B: RP-HPLC

591 chromatogram).

592

593

594


595

596

597

598

599



600

601 **Fig.2.** The angiotensin-I-converting enzyme(ACE) inhibitory activities of CPs fractions.

602

603

604

605

606

607

608

609

610

611

612

613

614

615


616

617

618


619

620



621

622



623

624 **Fig.3.** Stabilities of angiotensin-I-converting enzyme (ACE) inhibitory activities of CPs fractions.

625 (A) CPs with incubation at different temperatures; (B) CPs digestion *in vitro* by gastrointestinal

626 proteases. RACEI: Relative ACE inhibitory retention rate; The activity of the CPs prior to treatment

627 was considered as 100%.

628

629

630

631

632

633

634

635





Fig.4. Antihypertensive effects of CPs on spontaneous hypertensive rats (SHRs). The actual systolic blood pressure (SBP)(A) and diastolic blood pressure (DBP) (B) over the same time period following administration of the zein hydrolysate (50 mg/kg), CPs-2 (10 mg/kg), a positive control (captopril,10 mg/kg), and a saline solution (negative control). Data shown were the means \pm SD (n = 4).

665

666




667

668 **Fig. 5.** Identification of molecular mass and amino acid sequence of CPs-2-1. (A) IT-MS spectrum

669 of CPs-2-1. (B) IT-MS/MS spectrum of m/z 452.3.

Isolation and identification of a novel peptide from zein with antioxidant and antihypertensive activity



254x190mm (96 x 96 DPI)